Visitor information – Everything you need to know about visiting our sites.
Alfred Health research outcomes are published in a wide range of peer reviewed journals.
Search or browse research publications by year, research area, publication type or keyword.
Publication Details
A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
Ingles Garces AH, Ang JE, Ameratunga M, Ch»nard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U
(2018), Eur J Cancer, 104, 32-38
The value of participating in clinical trials: the whole is greater than the sum of its parts
Zalcberg JR, Friedlander M
(2018), Med J Aust, 209(10), 424-425
DOI: 10.5694/mja17.01266
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre
Moloney M, Faulkner D, Link E, Rischin D, Solomon B, Lim AM, Zalcberg JR, Jefford M, Michael M
(2018), Cancer Chemother Pharmacol, 82(5), 865-876
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW
Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C
(2018), J Gastroenterol Hepatol, 33(4), 814-824
DOI: 10.1111/jgh.14007
Biosimilars are coming: ready or not
Zalcberg J
(2018), Intern Med J, 48(9), 1027-1034
DOI: 10.1111/imj.14033
Rationale, Opportunities, and Reality of Biosimilar Medications
Zalcberg JR
(2018), N Engl J Med, 379(7), 694
DOI: 10.1056/NEJMc1808348
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
Goey KKH, Sørbye H, Glimelius B, Adams RA, Andr» T, Arnold D, Berlin JD, Bodoky G, de Gramont A, DÃaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M
(2018), Eur J Cancer, 100, 35-45
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD)
(2018), J Natl Cancer Inst, 110(6), 638-648
DOI: 10.1093/jnci/djx253
High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy
Chandrasekara S, Davis S, Thomson P, Haydon A
(2018), Asia Pac J Clin Oncol, 14(5), e442-7
DOI: 10.1111/ajco.12846
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudá R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM
(2017), Lancet, 390(10103), 1645-53
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS
(2017), Br J Cancer, 116(12), 1558-63
DOI: 10.1038/bjc.2017.142
Tumour mutation status and sites of metastasis in patients with cutaneous melanoma
Adler NR, Wolfe R, Kelly JW, Haydon A, McArthur GA, McLean CA, Mar VJ
(2017), Br J Cancer, 117(7), 1026-35
DOI: 10.1038/bjc.2017.254
Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalá M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM
(2017), N Engl J Med, 377(19), 1813-23
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, Haydon A
(2017), Br J Cancer, 117(7), 921-4
DOI: 10.1038/bjc.2017.253
Metastatic pathways in patients with cutaneous melanoma
Adler NR, Haydon A, McLean CA, Kelly JW, Mar VJ
(2017), Pigment Cell Melanoma Res, 30(1), 13-27
DOI: 10.1111/pcmr.12544
Immunotherapy for bladder cancer: rediscovering an old friend
Voskoboynik M, Rudman S, Arkenau HT, Hughes S, Chowdhury S
(2016), BJU Int, 117(5),
The Victorian Melanoma Service: a 20-year review of an Australian multidisciplinary cancer service
Meani RE, Pan Y, McLean C, Haydon A, Leung M, Kelly JW
(2016), Australas J Dermatol, 57(3),
Complete pathological response after neoadjuvant long-course chemoradiotherapy for rectal cancer and its relationship to the degree of T3 mesorectal invasion
Wilkins S, Haydon A, Porter I, Oliva K, Staples M, Carne P, McMurrick P, Bell S
(2016), Dis Colon Rectum, 59(5),
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro
(2016), J Clin Oncol, 34(19),